TY - JOUR T1 - Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions JF - Journal of Neurology, Neurosurgery & Psychiatry JO - J Neurol Neurosurg Psychiatry SP - 1065 LP - 1075 DO - 10.1136/jnnp-2013-307539 VL - 85 IS - 10 AU - Nadia Magdalinou AU - Andrew J Lees AU - Henrik Zetterberg Y1 - 2014/10/01 UR - http://jnnp.bmj.com/content/85/10/1065.abstract N2 - Parkinsonian diseases comprise a heterogeneous group of neurodegenerative disorders, which show significant clinical and pathological overlap. Accurate diagnosis still largely relies on clinical acumen; pathological diagnosis remains the gold standard. There is an urgent need for biomarkers to diagnose parkinsonian disorders, particularly in the early stages when diagnosis is most difficult. In this review, several of the most promising cerebrospinal fluid candidate markers will be discussed. Their strengths and limitations will be considered together with future developments in the field. ER -